Thereafter, we interfere with the expression of CAFs FASN by siRNA or reduce the uptake of fatty acids by CRC cells by SSO in vitro or CD36 monoclonal antibody in vivo, and the migration ability of CRC cells are significantly downregulated. The gene discussed is FASN; the disease is colorectal carcinoma.